Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 1;28(6):737-743.
doi: 10.4103/njcp.njcp_384_24. Epub 2025 Jun 25.

Circulating Endotrophin as a Biomarker of Fibrosis in Chronic Liver Diseases

H Eruzun  1 , U Avcıoğlu  1 , I Gören  1 , Y C Ürkmez  2 , Ö Küçükdemirci  1 , Bşç Zorlu  3 , E Isgandarov  4 , M Ustaoğlu  1 , T Ayyıldız  1 , B Yıldırım  1 , A Bektaş  1
Affiliations
Free article

Circulating Endotrophin as a Biomarker of Fibrosis in Chronic Liver Diseases

H Eruzun et al. Niger J Clin Pract. .
Free article

Abstract

Background: Liver fibrosis is a common consequence of most chronic inflammatory liver diseases and results in cirrhosis if left untreated. Therefore, it is important to detect early stages of fibrosis. Endotrophin, the cleavage product of collagen VI, plays a role in renal, cardiac, and hepatic fibrosis. In animal studies, expression of endotrophin results in hepatic inflammation and fibrosis.

Aim: We investigated the association between serum endotrophin levels and severity of liver fibrosis in patients with chronic hepatitis B (CHB), autoimmune liver diseases (ALD), and metabolic-associated steatotic liver disease (MASLD).

Methods: Blood samples were obtained from treatment-naive patients. Liver fibrosis was evaluated using the modified Knodell scoring system.

Results: We included 85 patients (28 with CHB, 32 with ALD and 25 with MASLD). In the combined group endotrophin levels were significantly higher in patients with advanced fibrosis compared to mild fibrosis (P=0.006). However, in the CHB group endotrophin levels were significantly lower compared to the other groups (P<0.001). Further, there was no difference between mild and advanced fibrosis in the individual groups.

Conclusions: Our preliminary data showed that endotrophin might be a clinically relevant biomarker for the assessment of liver fibrosis. However, etiology-specific larger-scale clinical studies are needed to determine the true utility of endotrophin as a biomarker in different chronic liver diseases.

Keywords: Chronic liver diseases; endotrophin; liver fibrosis; primary biliary cholangitis; steatotic liver diseases.

PubMed Disclaimer

References

R EFERENCES

    1. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol 2019;70:151–71.
    1. Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on hepatology practice: Past, present and future. J Hepatol 2022;76:1362–78.
    1. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431–5.
    1. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467–74.
    1. Oberti F, Valsesia E, Pilette C, Rousselet MC, Bedossa P, Aubé C, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997;113:1609–16.

LinkOut - more resources